This profile describes access and programme structure. Inclusion is not an endorsement, regulatory finding, or clinical recommendation. Prescription decisions belong to a qualified prescriber.
At a glance
Pricing, medicine, location, care, fulfilment, funding, and policy claims are separated below.
An open check means the public sources were not specific enough—not that the service failed the check.
Resumen en español
Found para usuarios hispanohablantes
Esta sección ofrece una orientación breve en español sobre el perfil estadounidense. La investigación completa de precios, acceso, farmacia y seguimiento permanece arriba mientras ampliamos la revisión editorial en español.
No encontramos una fuente primaria suficientemente específica para afirmar que una cita clínica esté disponible en español. Confirma el idioma y cualquier servicio de interpretación antes de pagar.
- si la cita concreta será en español;
- el coste mensual ordinario y qué incluye;
- la licencia estatal del profesional;
- el medicamento, la farmacia y el coste por separado.
Esta traducción editorial no demuestra que el proveedor ofrezca atención clínica en español y no sustituye una valoración médica.
Comparar proveedores para hispanohablantes en EE. UU. →How the program is structured
A multi-path metabolic-care program with compounded, direct-pay brand, insurance-assisted brand, and non-GLP-1 options. Longer commitments can produce lower effective monthly headlines, so formulation and term are central to comparison.
GLP.directory checked the cited public sources on Sep 13, 2026. We reviewed published access, cost, care, fulfilment, funding, cancellation, monitoring, and switching details; we have not audited individual clinical encounters, prescriptions, pharmacy operations, or outcomes.
Availability can change by state, clinician, medical history, product, pharmacy, inventory, and insurance plan. “Not publicly confirmed” means we did not find a sufficiently specific answer in the cited public material. Confirm the current patient-specific answer before paying or changing care.
Service configuration
These structured fields power the directory filters. They describe the reviewed public route and should be reconfirmed for the selected plan.
- Provider type
- Telehealth program
- Medicine context
- Semaglutide (Wegovy; Ozempic/Rybelsus for type 2 diabetes) · Tirzepatide (Zepbound; Mounjaro for type 2 diabetes) · Liraglutide (Saxenda; Victoza for type 2 diabetes)
- Formats reviewed
- Injection · Oral medicine
- Funding routes
- Private pay · Insurance support
- Service features
- Coaching · Clinician support · Switching pathway · Home delivery
- Access check
- Confirm current state access
- Evidence status
- Primary sources reviewed
- Research depth
- 2 cited sources · 4 medicine rows · 4 open checks
Recurring cost breakdown
- Compounded plans were advertised from $99/month with flat dose pricing on qualifying terms.
- Non-GLP-1 plans were advertised from $49/month.
- Three-, six-, and twelve-month commitments can produce different effective prices and upfront charges.
- Insurance copays, direct-pay brand prices, and labs are pathway-specific rather than represented by one headline.
- Medicine + dose
- Membership or consultation
- Delivery + supplies
- Labs + follow-up
- Renewal after offers
Medication and formulation matrix
| Medication | Form | Regulatory / program path | Published price view |
|---|---|---|---|
| Compounded semaglutide / tirzepatide | Weekly injection | Not FDA-approved | From $99/month on qualifying plan |
| Wegovy / Zepbound / Foundayo | Pill or injection as offered | FDA-approved brands | Insurance or direct-pay price |
| Ozempic / Mounjaro / Rybelsus / Saxenda / Trulicity / Victoza | Oral or injectable | FDA-approved; indications differ | Eligibility and route dependent |
| Metformin / topiramate / Contrave and other non-GLP options | Oral | Clinician-selected | Plans advertised from $49/month |
Important: “Compounded” means the product is not FDA approved. A brand approved for one condition is not automatically approved for another. The treating clinician determines whether any prescription is appropriate.
State-by-state availability
- Found publishes state eligibility within its program pages; treatment still varies by state and clinician.
- Verify the selected medication rather than treating general program availability as product availability.
Clinician access and follow-up cadence
- Board-certified metabolic-care clinicians design the plan.
- Care-team access is advertised between check-ins; exact synchronous visit cadence is plan-specific.
Pharmacy and fulfillment
- Eligible medication can ship to the patient’s door.
- Different brand, compounded, and insurance paths can use different pharmacies; confirm the dispenser for the selected plan.
Insurance and prior authorization
- Found offers insurance navigation as well as direct-pay alternatives.
- Prior authorization and formulary outcome are not guaranteed and can change both medication and total price.
Cancellation, refund, and commitment
- Commitment length is material; cancelling service does not necessarily erase an agreed multi-month financial term.
- Review the current pricing and membership terms for unused service and processed medication before purchase.
Labs, monitoring, and dose management
- Lab requirements and charges depend on the selected clinical pathway.
- No universal included lab panel was confirmed across every plan.
Maintenance and switching
- Found advertises plans for new and continuing patients.
- Compare exact medication source, dose, term, and support before treating a transfer as like-for-like.
Program snapshot
Program bundles vary
Profiled support: Ongoing clinician access, Coaching or behavior support.
Cash pay · Insurance help
Found advertises insurance navigation and direct-pay brand routes; neither guarantees a particular net price.
Verify before purchase
Ask which pharmacy handles the selected path and whether the formulation or fulfillment cadence changes by plan.
What the advertised program may include
- Clinician-designed plan
- Medication access when prescribed
- Insurance support on eligible paths
- Behavior and care support
Useful comparison signals
Based on the provider’s published program structure, this profile is tagged for the following searches. These are filters, not endorsements or clinical recommendations.
- Starting care and comparing first-provider requirements
- Switching providers or continuing an established treatment
- Comparing lower-cost access routes and recurring totals
- Ongoing clinician access
- Coaching or behavior support
Open evidence gaps
These are material details we could not confirm precisely enough from the cited public pages. They are the highest-priority questions to resolve directly.
- Named pharmacy by plan
- Universal lab pricing
- Guaranteed live-visit cadence
- Net brand cost before benefit review
Questions to ask before paying
- What is the ordinary recurring total after any introductory period?
- Does that total include clinician care, medication, supplies, labs, and shipping?
- Which clinician group and dispensing pharmacy will be responsible for my care?
- What happens to billing if I am not prescribed the advertised treatment?
- What records and timing do you require if I am switching from another provider?
Source ledger
Every entry below is a provider-controlled or official public source. A source link documents what was published; it does not independently validate performance, regulatory compliance, safety, or outcomes.
Medication breadth, clinical model, shipping and support
Plan terms and starting-price structure